Millennium Management LLC grew its holdings in Luminex Co. (NASDAQ:LMNX) by 10.4% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,038,865 shares of the medical instruments supplier’s stock after acquiring an additional 98,190 shares during the period. Millennium Management LLC’s holdings in Luminex were worth $21,889,000 as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of LMNX. Hancock Holding Co. bought a new stake in Luminex in the first quarter worth approximately $7,907,000. Renaissance Technologies LLC grew its position in Luminex by 17.5% in the fourth quarter. Renaissance Technologies LLC now owns 2,246,640 shares of the medical instruments supplier’s stock worth $44,259,000 after acquiring an additional 334,900 shares in the last quarter. DAFNA Capital Management LLC grew its position in Luminex by 810.0% in the first quarter. DAFNA Capital Management LLC now owns 227,500 shares of the medical instruments supplier’s stock worth $4,793,000 after acquiring an additional 202,500 shares in the last quarter. Deutsche Bank AG grew its position in Luminex by 83.1% in the fourth quarter. Deutsche Bank AG now owns 312,591 shares of the medical instruments supplier’s stock worth $6,156,000 after acquiring an additional 141,907 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in shares of Luminex by 17.6% in the fourth quarter. Bank of New York Mellon Corp now owns 677,060 shares of the medical instruments supplier’s stock worth $13,336,000 after buying an additional 101,468 shares during the last quarter. 81.88% of the stock is owned by institutional investors.
A number of brokerages have recently weighed in on LMNX. BidaskClub upgraded shares of Luminex from a “buy” rating to a “strong-buy” rating in a research note on Thursday, May 24th. Zacks Investment Research cut shares of Luminex from a “buy” rating to a “hold” rating in a research note on Thursday, May 10th. BTIG Research set a $26.00 price objective on shares of Luminex and gave the stock a “buy” rating in a research note on Tuesday, May 8th. ValuEngine upgraded shares of Luminex from a “hold” rating to a “buy” rating in a research note on Tuesday, May 8th. Finally, Deutsche Bank upgraded shares of Luminex from a “sell” rating to a “hold” rating and set a $22.00 price objective for the company in a research note on Monday, May 7th. Four research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. Luminex has an average rating of “Buy” and an average price target of $24.00.
In related news, SVP Todd C. Bennett sold 2,235 shares of the company’s stock in a transaction on Monday, May 14th. The shares were sold at an average price of $25.95, for a total transaction of $57,998.25. Following the completion of the transaction, the senior vice president now directly owns 21,309 shares in the company, valued at approximately $552,968.55. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director G Walter Loewenbaum II sold 40,797 shares of the company’s stock in a transaction on Friday, June 22nd. The shares were sold at an average price of $31.03, for a total transaction of $1,265,930.91. Following the transaction, the director now owns 491,151 shares of the company’s stock, valued at $15,240,415.53. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 95,496 shares of company stock valued at $2,777,427. Corporate insiders own 7.40% of the company’s stock.
Shares of Luminex opened at $29.53 on Friday, Marketbeat reports. Luminex Co. has a 1-year low of $18.62 and a 1-year high of $31.17. The firm has a market capitalization of $1.28 billion, a PE ratio of 32.45, a PEG ratio of 2.80 and a beta of 0.16.
Luminex (NASDAQ:LMNX) last issued its quarterly earnings data on Monday, May 7th. The medical instruments supplier reported $0.30 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.22 by $0.08. Luminex had a net margin of 10.60% and a return on equity of 8.07%. The business had revenue of $82.60 million during the quarter, compared to analysts’ expectations of $80.52 million. During the same period in the previous year, the company earned $0.28 earnings per share. Luminex’s revenue for the quarter was up 6.2% on a year-over-year basis. research analysts anticipate that Luminex Co. will post 0.75 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, July 13th. Investors of record on Friday, June 22nd will be paid a dividend of $0.06 per share. This represents a $0.24 annualized dividend and a yield of 0.81%. The ex-dividend date of this dividend is Thursday, June 21st. Luminex’s payout ratio is currently 26.37%.
Luminex Company Profile
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, an automated multiplex-capable system.
Want to see what other hedge funds are holding LMNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Luminex Co. (NASDAQ:LMNX).
Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.